Certainly! Here are the results from using Abecma (idecabtagene vicleucel) for treating myeloma:

- Approval: Abecma was approved by the FDA in 2021 for treating relapsed or refractory multiple myeloma after four or more prior therapies
- Response Rates:
- Overall Response Rate: 72% of participants had a complete or read more

Certainly! Here are the results from using Abecma (idecabtagene vicleucel) for treating myeloma:

- Approval: Abecma was approved by the FDA in 2021 for treating relapsed or refractory multiple myeloma after four or more prior therapies.
- Response Rates:
- Overall Response Rate: 72% of participants had a complete or partial reduction in tumor burden.
- Complete Response Rate: 33% of participants had a complete response.
- Duration of Response: 65% of those with a complete response maintained it for at least 12 months.
- Side Effects:
- Commonly reported side effects include low blood cell counts.
- Potential for cytokine release syndrome and nervous system problems.

For more detailed information, please refer to the provided resources or consult with your oncologist.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

CAR-T Cell Therapy for Multiple Myeloma: What Is It? | MyMyelomaTeam

Abecma (Idecabtagene vicleucel) for Myeloma | MyMyelomaTeam